Lazard Asset Management
ITOS

Lazard Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Lazard Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-57,743
Closed -$589K – 2402
2024
Q3 		$589K Buy
+57,743
New +$881K ﹤0.01% 1315
2023
Q2 		– Sell
-6,177
Closed -$84K – 2417
2023
Q1 		$84K Hold
6,177
– – ﹤0.01% 1603
2022
Q4 		$120K Hold
6,177
– – ﹤0.01% 1455
2022
Q3 		$117K Sell
6,177
-710
-10% -$16.4K ﹤0.01% 1413
2022
Q2 		$141K Buy
6,887
+3,051
+80% +$72.4K ﹤0.01% 1379
2022
Q1 		$123K Sell
3,836
-1
-0% -$36 ﹤0.01% 1344
2021
Q4 		$178K Buy
+3,837
New +$128K ﹤0.01% 1302

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Lazard Asset Management's ITOS Position: Q4 2024 in Review

Lazard Asset Management sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 57,743 shares — an estimated $589K sold.

Lazard Asset Management first reported a position in ITOS in Q4 2021 and held it in 7 quarters. The position peaked at $589K in Q3 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Lazard Asset Management reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 57,743 iTeos Therapeutics shares in Q4 2024, an estimated $589K.
  • Lazard Asset Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 7 quarters.
  • Lazard Asset Management's iTeos Therapeutics position peaked at $589K in Q3 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.